178 related articles for article (PubMed ID: 21858533)
21. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
22. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
Brunsvig PF; Aamdal S; Gjertsen MK; Kvalheim G; Markowski-Grimsrud CJ; Sve I; Dyrhaug M; Trachsel S; Møller M; Eriksen JA; Gaudernack G
Cancer Immunol Immunother; 2006 Dec; 55(12):1553-64. PubMed ID: 16491401
[TBL] [Abstract][Full Text] [Related]
23. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
24. High Peptide Dose Vaccination Promotes the Early Selection of Tumor Antigen-Specific CD8 T-Cells of Enhanced Functional Competence.
Carretero-Iglesia L; Couturaud B; Baumgaertner P; Schmidt J; Maby-El Hajjami H; Speiser DE; Hebeisen M; Rufer N
Front Immunol; 2019; 10():3016. PubMed ID: 31969886
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
Vonderheide RH; Domchek SM; Schultze JL; George DJ; Hoar KM; Chen DY; Stephans KF; Masutomi K; Loda M; Xia Z; Anderson KS; Hahn WC; Nadler LM
Clin Cancer Res; 2004 Feb; 10(3):828-39. PubMed ID: 14871958
[TBL] [Abstract][Full Text] [Related]
26. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Sanborn RE; Ross HJ; Aung S; Acheson A; Moudgil T; Puri S; Hilton T; Fisher B; Coffey T; Paustian C; Neuberger M; Walker E; Hu HM; Urba WJ; Fox BA
J Immunother Cancer; 2017 Dec; 5(1):103. PubMed ID: 29258618
[TBL] [Abstract][Full Text] [Related]
27. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
[TBL] [Abstract][Full Text] [Related]
28. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
[TBL] [Abstract][Full Text] [Related]
29. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
30. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
[TBL] [Abstract][Full Text] [Related]
32. HLA-A2 and B35 restricted hantaan virus nucleoprotein CD8+ T-cell epitope-specific immune response correlates with milder disease in hemorrhagic fever with renal syndrome.
Ma Y; Wang J; Yuan B; Wang M; Zhang Y; Xu Z; Zhang C; Zhang Y; Liu B; Yi J; Yang K; Yang A; Zhuang R; Jin B
PLoS Negl Trop Dis; 2013; 7(2):e2076. PubMed ID: 23469304
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
[TBL] [Abstract][Full Text] [Related]
34. Expansion of quiescent lung adenocarcinoma CD8+ T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes.
Atzin-Méndez JA; López-González JS; Báez R; Arenas-Del Angel MC; Montaño LF; Silva-Adaya D; Lascurain R; Gorocica P
Oncol Rep; 2016 Jan; 35(1):33-42. PubMed ID: 26498650
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW; Walker EB; Fox BA; Haley D; Wisner KP; Doran T; Fisher B; Justice L; Wood W; Vetto J; Maecker H; Dols A; Meijer S; Hu HM; Romero P; Alvord WG; Urba WJ
J Clin Oncol; 2003 Apr; 21(8):1562-73. PubMed ID: 12697882
[TBL] [Abstract][Full Text] [Related]
37. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
Ellingsen EB; Aamdal E; Guren T; Lilleby W; Brunsvig PF; Mangsbo SM; Aamdal S; Hovig E; Mensali N; Gaudernack G; Inderberg EM
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35613827
[TBL] [Abstract][Full Text] [Related]
38. CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
Cornet S; Menez-Jamet J; Lemonnier F; Kosmatopoulos K; Miconnet I
Vaccine; 2006 Mar; 24(11):1880-8. PubMed ID: 16300869
[TBL] [Abstract][Full Text] [Related]
39. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.
Liu F; Zhang H; Shen D; Wang S; Ye Y; Chen H; Pang X; Song Q; He P
J Gastroenterol; 2014 Mar; 49(3):419-26. PubMed ID: 23604623
[TBL] [Abstract][Full Text] [Related]
40. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
